Overview
Approximately 219 individuals with acute, subacute or
chronic low back pain are being allocated in a 1:1:1
ratio to receive either 13 HVLA-SM treatments over 6
Wilder et al. Trials 2011, 12:161
http://www.trialsjournal.com/content/12/1/161
Page 3 of 15
weeks to the lumbar and pelvic region, 13 LVVA-SM
treatments over 6 weeks to the lumbar and pelvic
region, or 2 weeks of a sham treatment followed by 4
weeks of full spine “doctor’s choice” SM. Primary and
secondary outcomes are assessed at baseline visit 2
(BL2), week 2 and week 6 by assessors blinded to treatment
assignment.